CX-659S

• Description:

  CX-659S is an orally active and novel derivative of 5-carboxamide uracil. CX-659S can effectively inhibit lipid peroxidation (IC50 = 5.9 μM) . CX-659S can reduce the infiltration of neutrophils and eosinophils. CX-659S inhibits the mRNA expression of pro-inflammatory cytokines IL-1β and TNF-α. CX-659S can be used for research on inflammatory conditions[1].

• UNSPSC:

  12352005

• Target:

  Interleukin Related; TNF Receptor

• Related Pathways:

  Apoptosis; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  CC1=C2C (CC[C@] (C) (O2) C (NC3=C (N (C4=CC=CC=C4) C (N (C3=O) C) =O) N) =O) =C (C (O) =C1C) C

• Molecular Formula:

  C25H28N4O5

• Molecular Weight:

  464.51

• References & Citations:

  [1]Tobe M, et al. Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction. Bioorg Med Chem. 2000 Aug;8 (8) :2037-47. |[2]Goto Y, et al. Suppressive effect of topically applied CX-659S, a novel diaminouracil derivative, on the contact hypersensitivity reaction in various animal models. Int Arch Allergy Immunol. 2000 Dec;123 (4) :341-8.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IL-1

• CAS Number:

  204980-81-4